Abstract
Nine new synthetic compounds, structurally related to the most active glycoglycerolipid analogues carrying a hexanoyl chain, were tested for their anti-tumor-promoting activity using a short-term in vitro assay for Epstein–Barr virus (EBV) activation. All these compounds, in which the ester function is replaced by different metabolically more stable groups, were almost as active as their ester reference compounds in inhibiting the EBV activation promoted by the tumor promoter 12- O-tetradecanoylphorbol-13-acetate (TPA). Two of these, devoid of any functionality on the lipophilic chain, when tested in an in vivo two-stage carcinogenesis test, exhibited marked inhibitory effects on mouse skin tumor promotion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
